Objective:

2

A polymerase Chain reaction(PCR) identification method for Suis Fellis Pulvis and its Chinese patent medicines was established to provide an example for the identification of animal-derived components in complex components.

Method:

2

A PCR identification method was established based on swine derivatives identification primers

the reaction system was optimized

and the established method was investigated and verified. By the established PCR identification method

the swine derivatives of 20 batches of self-made Suis Fellis Pulvis material

19 batches of commercially available Suis Fellis Pulvis and 22 batches of Chinese patent medicines containing Suis Fellis Pulvis were identified. The commercially available Suis Fellis Pulvis material and Chinese patent medicines containing Suis Fellis Pulvis positive products that were amplified PCR were verified by enzyme digestion and sequencing.

Result:

2

Totally 20 batches of self-made Suis Fellis Pulvis material and Suis Fellis Pulvis control material could expand the specific identification band of about 212 bp

and there was no bands in bovine and ovine reference

only 5 batches of the 19 batches of commercially available Suis Fellis Pulvis had expanded specific identification bands

10 batches of 22 batches of Chinese patent medicines containing Suis Fellis Pulvis were detected to have swine derivatives

the Suis Fellis Pulvis control material and the PCR-amplified commercially available Suis Fellis Pulvis material positive products can produce about 200 bp of bands after digestion with

Mnl

I. The highest similarity between the amplification products sequence of Suis Fellis Pulvis and its Chinese patent medicines

and the GenBank database was

Sus scrofa

the consistency was 99%

which conformed to the sequence of swine.

Conclusion:

2

The PCR identification method established in this paper can accurately identify the biological origin of Suis Fellis Pulvis and its Chinese patent medicines.